Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822328 | 0.92 | CRBN (0.53) | CRBNALDH1A1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL6825585 | 0.92 | CRBN (0.53) | CRBNALDH1A1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL10228581 | 0.90 | ALDH1A1 (0.53) | CRBNALDH1A1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL16179163 | 0.87 | KCNH2 (0.50) | CRBNALDH1A1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL14538238 | 0.87 | CRBN (0.52) | CRBNALDH1A1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL2114546 | 0.81 | AOC2 (0.51) | CRBNALDH1A1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL16179104 | 0.81 | CRBN (0.47) | CRBNALDH1A1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL28956797 | 0.80 | SLC12A2 (0.49) | CRBNALDH1A1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL18205613 | 0.79 | NPSR1 (0.48) | CRBNALDH1A1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4595077 | 0.79 | CRBN (0.55) | CRBNALDH1A1CYP3A4CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196888-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2012-08-02 | — | — | US | claimed |
| US-20120156290-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2012-06-21 | — | — | US | claimed |
| WO-2019149260-A1 | PYRIDAZINOL COMPOUND, DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2019-08-08 | — | — | WO | disclosed |
| US-9487532-B2 | Process for preparing oxymorphone, naltrexone, and buprenorphine | PENICK CORPORATION (US) | 2016-11-08 | — | — | US | disclosed |
| US-9108974-B2 | Process for preparing oxymorphone, naltrexone, and buprenorphine | PENICK CORPORATION (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2332410-B1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORP (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20140051861-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2014-02-20 | — | — | US | disclosed |
| US-8357802-B2 | Process for preparing oxymorphone | PENICK CORPORATION (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120330017-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120196888-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120156290-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2332409-A1 | Process for preparing oxymorphone, naltrexone and buprenorphine | Penick Corporation (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-2332410-A1 | Process for preparing oxymorphone, naltrexone, and buprenorphine | Penick Corporation (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110118466-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100274019-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2076131-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | Penick Corporation (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080125592-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2008048957-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | PENICK CORPORATION (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120330017-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | OPRK1, OPRD1, OPRM1 | CRBN 4655/4885ALDH1A1 405/4885CYP2C9 50/4885 |
| US-20140051861-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | OPRK1, OPRD1, OPRM1 | CRBN 4655/4885ALDH1A1 405/4885CYP2C9 50/4885 |
| US-20080125592-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | OPRK1, OPRD1, OPRM1 | CRBN 4655/4885ALDH1A1 405/4885CYP2C9 50/4885 |
| US-20120156290-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | OPRK1, OPRD1, OPRM1 | CRBN 4655/4885ALDH1A1 405/4885CYP2C9 50/4885 |
| US-20100274019-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | OPRK1, OPRD1, OPRM1 | CRBN 4655/4885ALDH1A1 405/4885CYP2C9 50/4885 |
| US-20120196888-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | OPRK1, OPRD1, OPRM1 | CRBN 4655/4885ALDH1A1 405/4885CYP2C9 50/4885 |
| US-20110118466-A1 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE | OPRK1, OPRD1, OPRM1 | CRBN 4655/4885ALDH1A1 405/4885CYP2C9 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.